Long-acting lenacapavir is a breakthrough for preventing HIV infection, but HIV vaccine research must continue.
10.1007/s11684-025-1137-3
- Author:
Caijun SUN
1
;
Linghua LI
2
;
Pingchao LI
3
;
Weiping CAI
2
;
Xiaoping TANG
2
;
Yiming SHAO
4
;
Ling CHEN
5
Author Information
1. School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, 518107, China.
2. Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, 510440, China.
3. Institute of Drug Discovery, Guangdong Laboratory of Computational Biomedicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530, China.
4. Changping National Laboratory, Beijing, 102206, China. yshao@chinaaids.cn.
5. Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, 510440, China. chen_ling@gibh.ac.cn.
- Publication Type:Journal Article
- From:
Frontiers of Medicine
2025;19(3):543-547
- CountryChina
- Language:English
